Daniel Bischoff
Papers
1
Total Citations
66
H-Index
1
About
Daniel Bischoff is a leading figure in respiratory drug discovery, specializing in the development of advanced in vitro models of the human airway. His primary research focuses on miniaturizing and optimizing air-liquid interface (ALI) epithelial cultures to overcome the critical bottleneck of limited primary cell availability from clinical samples. Bischoff’s most notable contribution is the creation of a miniaturized 96-Transwell ALI human small airway epithelial model, a breakthrough that enables high-throughput screening of respiratory therapeutics using far fewer cells than traditional methods. This work, published in 2020, has garnered 66 citations and is widely recognized for its practical impact on preclinical drug testing. By addressing the restrained capacity of airway cells to divide ex vivo, Bischoff’s platform accelerates the evaluation of drug candidates for diseases like asthma, COPD, and cystic fibrosis. His achievements underscore a commitment to bridging the gap between clinical scarcity and experimental demand, making him a pivotal innovator in respiratory pharmacology and a key resource for researchers seeking scalable, physiologically relevant models.
Research Focus
Key Achievements
Top Papers
- 1